



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

REGION 8

1595 Wynkoop Street

DENVER, CO 80202

Phone 800-227-8917

<http://www.epa.gov/region08>

January 24, 2021

Ref: 8WD-CWW

**SENT VIA EMAIL**  
**ELECTRONIC READ RECEIPT REQUESTED**

Suzette Smith  
EHS Manager  
Corixa Corporation dba GlaxoSmithKline Vaccines (GSK-Hamilton)  
[Suzette.M.Smith@gsk.com](mailto:Suzette.M.Smith@gsk.com)

Re: EPA Pretreatment Notification of Categorical Industrial User Requirements, ICIS Number:  
MT-PF00103

Dear Ms. Smith:

On May 6, 2019, the U.S. Environmental Protection Agency (EPA) conducted an inspection of the Corixa Corporation dba GlaxoSmithKline Vaccines (GSK-Hamilton). Based on information gathered during the inspection and information submitted by GSK-Hamilton in the July 22, 2020 application for the Notification of Discharge Requirements, GSK-Hamilton is subject to the Pharmaceutical Manufacturing Point Source Category Pretreatment Standards at 40 CFR Part 439. GSK-Hamilton is an industrial user of the City of Hamilton's publicly owned treatment works (POTW), which does not have a Pretreatment Program approved by EPA. Therefore, EPA directly oversees compliance of industrial users that discharge to the City of Hamilton POTW and is partnering with the City of Hamilton to ensure the POTW is protected from potential impacts of pollutants discharged from non-domestic sources.

Enclosed is information regarding GSK-Hamilton's discharge requirements as a categorical industrial user, subject to the Pharmaceutical Manufacturing Point Source Category Pretreatment Standards at 40 CFR Part 439 (Enclosure 1, Notification of Discharge Requirements). This enclosure sets forth specific effluent limits, monitoring frequencies and reporting requirements EPA has established in accordance with 40 CFR Part 403 in addition to applicable Categorical Pretreatment Standards and Pretreatment Requirements. Enclosure 2 is the associated Fact Sheet, which provides a rationale for the conditions set forth in Enclosure 1.

The Notification of Discharge Requirements and Fact Sheet were public noticed in the Ravalli Republic newspaper and on EPA's website on December 23, 2020 for a 30-day public comment period. There were no substantial comments received.

The Pretreatment Regulations at 40 CFR 403.12(j) require GSK-Hamilton to promptly notify the EPA and POTW in advance of any substantial change in the volume or character of pollutants in its discharge that may affect the regulatory requirements contained in this notification. These substantial changes could include changes to the operations, wastestream generation, and/or wastewater management that may affect the status of GSK-Hamilton under the Pretreatment Regulations.

Nothing contained in this notification package or in any EPA regulations restrict State or local agencies from imposing additional requirements in accordance with applicable laws, including requirements which are more stringent than those imposed by EPA.

If you have any questions about the enclosed information, please contact Al Garcia at 303-312-6382 or [garcia.al@epa.gov](mailto:garcia.al@epa.gov).

Sincerely,

Stephanie Dejong, Chief  
Wastewater Section

Enclosures:

1. Notification of Discharge Requirements under the Pharmaceutical Source Category and the General Pretreatment Regulations
2. GSK-Hamilton Fact Sheet

cc:

Donny Ramer, Public Works Director, City of Hamilton  
Rainie Devaney, NPDES Permits Unit, MTDEQ